The medtech space led by Intuitive Surgical (ISRG), Varian Medical Systems (VAR) and Steris (STE) has proved to be a safe haven in 2017, riding out drug-pricing fears that have weighed down Big Pharma and biotech stocks.
Meanwhile, even as political pressure mounts over the effort to “repeal and replace” ObamaCare, the medtech sector seemingly has bipartisan support to end the Medical Device Tax, a 2.3% tax on medical device sales in the U.S. Congress placed a moratorium on the tax two years ago.
The combination has made the space ripe for generalist investors fleeing the risks of biotech and pharma for more security, KeyBanc analyst Matt Mishan told Investor’s Business Daily. The sector’s strength reflects a growth in medical procedures as Baby Boomers hit their golden years.
“When you consider the landscape out there, health care looks good,” he said. “It’s a large piece of the economy. If you want to tie yourself to something, you want to tie yourself to volumes, which are tied to demographics. The older the population gets, the more procedures they have.”
Recommendations on how we should use AI, genomics and medtech in the NHS – click here for 98 pages to guide us to the future. ‘The greatest challenge is the culture shift in learning and innovation, with a willingness to embrace technology for system-wide improvement. An ambitious drive “towards the NHS becoming the world’s largest learning organisation”’.
You're the expert! Write for The Engine or share your articles, papers and researchAdd your content
Add your content
Sign up for Ignition, our regular, ideas-packed newsletter